RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Clinical trials for RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK trials appear
Sign up with your email to follow new studies for RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug tested for Tough-to-Treat head and neck cancers
Disease control CompletedThis study tested an experimental drug called ozuriftamab vedotin (BA3021) in people with advanced head and neck cancer that had returned or spread. The main goals were to see if the drug could shrink tumors and how safe it was. It included 42 adults whose cancer was not curable …
Matched conditions: RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Apr 02, 2026 02:42 UTC
-
New drug combo tested for Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested a combination of two drugs, duvelisib and docetaxel, for people with advanced head and neck cancer that had returned or spread after their first treatment stopped working. The goal was to see if this new combination could help control the cancer. About 26 people…
Matched conditions: RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC